RxDoctor Payments Data

Robert Smith, MD

Ophthalmology · West Valley City, UTNPI 1578675633

Payments from drug & device makers

$1,236in general payments, 2019–2025

Across 38 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$250
  • Amgen$205
  • AbbVie$186
  • Sun Pharmaceutical Industries Inc.$160
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$144
  • Johnson & Johnson Surgical Vision, Inc.$92
  • plus $199 from 7 others

What the payments were for

  • Food & beverage$1,21798%
  • Other$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,236 in reported general payments places this provider in the 50th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$117,140
Medicare patients
429
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost265$125,670
RestasisCyclosporine14$14,431
XiidraLifitegrast14$14,237
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$7,147
Prednisolone Acetate207$6,338
CombiganBrimonidine Tartrate/Timolol16$5,990
Latanoprost441$4,676
MoxifloxacinMoxifloxacin Hcl161$4,629
SimbrinzaBrinzolamide/Brimonidine Tart17$4,325
Alphagan PBrimonidine Tartrate21$4,276
Brimonidine Tartrate75$3,497
Cyclosporine15$3,312
Travoprost16$3,269
Ketorolac Tromethamine71$1,614
Timolol Maleate101$1,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$186$150,367316 claims
Bausch & Lomb Americas Inc.Xiidra$250$14,23714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 191 ophthalmology providers in Utah.

Other ophthalmology in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →